Ibrutinib Capsules and tablets bulk supplier for pharma manufacturers

Ibrutinib Capsules And Tablets Suppliers & Bulk Manufacturers

Available Forms: Capsules and tablets

Available Strengths: Capsule:140 mg, 70 mg; Tablet: 140 mg

Reference Brands: Imbruvica®(US & EU)

Ibrutinib (brand name Imbruvica®) is a BTK inhibitor used to treat B-cell malignancies like CLL, MCL, and Waldenström's macroglobulinemia. It works by blocking Bruton’s tyrosine kinase to prevent cancerous B-cell growth. Available in oral capsules (70 mg, 140 mg) and oral tablets (140 mg), it is approved in both the US and EU. Marketed by AbbVie and Janssen Pharmaceuticals, Imbruvica® is a crucial B2B oncology product for healthcare providers.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Ibrutinib (brand name Imbruvica®) is a BTK inhibitor used in oncology and hematology to treat B-cell malignancies like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. By blocking Bruton’s tyrosine kinase (BTK), Ibrutinib disrupts B-cell signaling, preventing cancerous B-cell growth. Available in oral capsules (70 mg, 140 mg) and oral tablets (140 mg), it is approved for use in both the US and EU. Marketed by AbbVie and Janssen Pharmaceuticals, Imbruvica® is a key product for B2B pharmaceutical transactions in the oncology and hematology sectors.

Ibrutinib Capsules And Tablets — third party manufacturing & bulk supply

Ibrutinib Capsules And Tablets is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Ibrutinib Capsules And Tablets is supplied as Capsules and tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Ibrutinib Capsules And Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Ibrutinib Capsules And Tablets →

Back to Listing

Frequently Asked Questions

Ibrutinib Capsules and tablets is listed as Capsules and tablets in Capsule:140 mg, 70 mg; Tablet: 140 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Ibrutinib Capsules and tablets is referenced against Imbruvica®(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.